Clinical Trial
doi: 10.1016/0022-4731(90)90016-l.
Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminary communication
Affiliations
- PMID: 2142244
- DOI: 10.1016/0022-4731(90)90016-l
Item in Clipboard
Clinical Trial
Response to toremifene (Fc-1157a) therapy in tamoxifen failed patients with breast cancer. Preliminary communication
J Steroid Biochem.
.
Abstract
Nine patients with measurable lesions of locally advanced or recurrent breast cancer have been treated with toremifene 200 mg daily. A response rate of 33% [complete remission (CR) + partial remission (PR)] or 78% [CR + PR + no change (NC)] has been achieved so far. As all our patients had previously relapsed on anti-oestrogen therapy (tamoxifen), we postulate that our response rate was achieved by a direct oncolytic effect.
Similar articles
-
Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communication.J Steroid Biochem. 1990 Jun 22;36(3):235-6. doi: 10.1016/0022-4731(90)90014-j. J Steroid Biochem. 1990. PMID: 2142242
-
Safety and efficacy of toremifene in breast cancer patients. A phase II study.J Steroid Biochem. 1990 Jun 22;36(3):229-31. doi: 10.1016/0022-4731(90)90012-h. J Steroid Biochem. 1990. PMID: 2142240 Clinical Trial.
-
Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication.J Steroid Biochem. 1990 Jun 22;36(3):227-8. doi: 10.1016/0022-4731(90)90011-g. J Steroid Biochem. 1990. PMID: 2142239
-
Phase II trials with toremifene in advanced breast cancer: a review.Breast Cancer Res Treat. 1990 Aug;16 Suppl:S31-5. doi: 10.1007/BF01807142. Breast Cancer Res Treat. 1990. PMID: 2149283 Review.
-
Alternate antiestrogens and approaches to the prevention of breast cancer.J Cell Biochem Suppl. 1995;22:51-7. doi: 10.1002/jcb.240590808. J Cell Biochem Suppl. 1995. PMID: 8538210 Review.
Cited by
-
Toremifene in postmenopausal breast cancer. Efficacy, safety and cost.Drugs Aging. 1997 Oct;11(4):261-70. doi: 10.2165/00002512-199711040-00002. Drugs Aging. 1997. PMID: 9342556 Review.
-
High dose toremifene for estrogen and progesterone receptor negative metastatic breast cancer: a phase II trial of the Cancer and Leukemia Group B (CALGB).Breast Cancer Res Treat. 1995;36(1):35-40. doi: 10.1007/BF00690182. Breast Cancer Res Treat. 1995. PMID: 7579504 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials